01. Foundational / Icons / 32x32px/Menu @1x Open Menu 01. Foundational / Icons / 32x32px/Close @1x Close Menu

Actor Portrayal

Did you know that rotavirus strains vary from season to season?

Only RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent) is indicated to help protect against RGE caused by 5 strains, including G2.a,b

Image Comparing the 5 rotavirus Strains Covered with RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent) vs. 4 Strains With Rotarix.Image Comparing the 5 rotavirus Strains Covered with RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent) vs. 4 Strains With Rotarix.

Why G2 rotavirus strain coverage matters1

Since rotavirus strains vary season to season, it’s important to have coverage that includes G2.1 Of the several strains identified in a postvaccination era study, G2 has been responsible for a number of rotavirus cases in the US. G2 is genetically distinct from other common rotavirus types.1-3

Prevalent rotavirus strains varied each season in the US between 2006 – 2016

Image Showing How Prevalent Rotavirus Strains Vary By Season Each Year in The USImage Showing How Prevalent Rotavirus Strains Vary By Season Each Year in The US

The most recent published data showed G2P[4] has been present over past seasons in the US.1,a

>20% of RGE cases reported in 2 of 3 most recently tracked rotavirus seasons were due to the G2 strain.1,a,b

Mixed, mixed genotypes; n, number of samples genotyped; NT, non-typeable genotypes.

aRotavirus seasons 2014, 2015, and 2016. The NVSN conducted active surveillance for hospitalization visits to the emergency department due to acute gastroenteritis in children <3 years of age from 3 US counties during the 2006 to 2016 seasons. Among 6,954 whole stool specimens collected, 928 tested positive for rotavirus and were submitted to the CDC for genotyping.1

bRotavirus season is defined as December through June.4

CDC, Centers for Disease Control and Prevention; NVSN, New Vaccine Surveillance Network; RGE, rotavirus gastroenteritis.

Actual size not shown
Actual size not shown

Looking to stock RotaTeq in your practice?

Simply register or log in to your account to get started.

Order RotaTeq today

ACIP recommendations

Find out about the ACIP recommendations for rotavirus vaccination in pediatric patients.5

See the ACIP recommendations

Dosing and administration

Review the dosing schedule and administration of RotaTeq.

Learn more

References

  1. Staat MA, Payne DC, Halasa N, et al. Continued evidence of the impact of rotavirus vaccine in children less than 3 years of age from the United States New Vaccine Surveillance Network: a multisite active surveillance program, 2006-2016. Clin Infect Dis. 2020;71(9):e421-e429. doi:10.1093/cid/ciaa150
  2. Dennis AF, McDonald SM, Payne DC, et al. Molecular epidemiology of contemporary G2P[4] human rotaviruses cocirculating in a single U.S. community: footprints of a globally transitioning genotype. J Virol. 2014;88(7):3789-3801. doi:10.1128/JVI.03516-13
  3. Matthijnssens J, Van Ranst M. Genotype constellation and evolution of group A rotaviruses infecting humans. Curr Opin Virol. 2012;2(4):426-433. doi:10.1016/j.coviro.2012.04.007
  4. Centers for Disease Control and Prevention (CDC). Rotavirus, about the vaccine. Updated March 25, 2021. Accessed May 29, 2024. https://www.cdc.gov/vaccines/vpd/rotavirus/hcp/about-vaccine.html
  5. Advisory Committee on Immunization Practices (ACIP). Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2024. Accessed May 29, 2024. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf
ExternalSitePopup

By clicking on this link, you will be leaving Merck Vaccines.

Cancel
Proceed
Cancel
Proceed

Indications and Usage for RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent)

RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.

 

The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.

Selected Safety Information for RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent)

RotaTeq should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine.

 

Infants with Severe Combined Immunodeficiency Disease (SCID) should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered RotaTeq and later identified as having SCID.

 

Infants with a history of intussusception should not receive RotaTeq.

 

No safety or efficacy data are available from clinical trials regarding the administration of RotaTeq to infants who are potentially immunocompromised.

 

In a post-marketing observational study in the US, cases of intussusception were observed in temporal association within 21 days following the first dose of RotaTeq, with a clustering of cases in the first 7 days.

 

No safety or efficacy data are available for administration of RotaTeq to infants with a history of gastrointestinal disorders.

 

Vaccine virus transmission from vaccine recipient to nonvaccinated contacts has been reported. Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts.

 

In clinical trials, the most common adverse events included diarrhea, vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm.

 

In post-marketing experience, intussusception (including death) and Kawasaki disease have been reported in infants who have received RotaTeq.

 

RotaTeq may not protect all vaccine recipients against rotavirus.

 

Before administering RotaTeq, please read the accompanying Prescribing Information. The Patient Product Information also is available.

Indications and Usage for RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent)

RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.

 

The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.

RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children

RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.

Selected Safety Information for RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent)

RotaTeq should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine.

 

Infants with Severe Combined Immunodeficiency Disease (SCID) should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered RotaTeq and later identified as having SCID.

 

Infants with a history of intussusception should not receive RotaTeq.

 

No safety or efficacy data are available from clinical trials regarding the administration of RotaTeq to infants who are potentially immunocompromised.

 

In a post-marketing observational study in the US, cases of intussusception were observed in temporal association within 21 days following the first dose of RotaTeq, with a clustering of cases in the first 7 days.

 

No safety or efficacy data are available for administration of RotaTeq to infants with a history of gastrointestinal disorders.

 

Vaccine virus transmission from vaccine recipient to nonvaccinated contacts has been reported. Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts.

 

In clinical trials, the most common adverse events included diarrhea, vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm.

 

In post-marketing experience, intussusception (including death) and Kawasaki disease have been reported in infants who have received RotaTeq.

 

RotaTeq may not protect all vaccine recipients against rotavirus.

 

Before administering RotaTeq, please read the accompanying Prescribing Information. The Patient Product Information also is available.

RotaTeq should not be administered to infants with a demonstrated history of hypersensitivity

RotaTeq should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine.

Infants with Severe Combined Immunodeficiency Disease (SCID) should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged